Compare Booz Allen Hamilton Holding Corporation (BAH) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs Mesoblast Limited — how do they compare? Booz Allen Hamilton Holding Corporation trades at $78.41 (market cap $9.45B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Booz Allen Hamilton Holding Corporation is far larger — about 4.3× Mesoblast Limited's market cap, and Booz Allen Hamilton Holding Corporation pays a 3% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| BAH | MESO | |
|---|---|---|
Market Cap | $9.45B | $2.21B |
Sector | Industrials | Technology |
52-Week High | $111.63 | $20.96 |
52-Week Low | $59.71 | $12.88 |
Enterprise Value | $13.07B | $2.21B |
Dividend Yield | 3% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
